Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit these popular categories the hardest.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

(Even larger is U.S.-based Eli Lilly & Co. the maker of Zepbound and Mounjaro ... For example, Impact Analytics found that sales for smaller-sized women’s shirts increased by 12.1%, based on a survey ...

Of the two stocks, Eli Lilly looks better poised to benefit from the current weight-loss drug craze. Tirzepatide is a very effective molecule and, as a result, Zepbound has been a hot seller for ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Crucially, CagriSema had been seen as Novo Nordisk’s opportunity to beat Eli Lilly’s Zepbound, which was approved in November 2023 and quickly won market share. Results published in December ...